A private biotechnology company based in Chicago, Grove Biopharma, specializes in developing protein-like polymers known as PLPs. These PLPs are innovative biologics designed to target difficult intracellular drug targets. Grove Biopharma recently revealed preclinical findings showing successful targeted degradation of two crucial oncogenic drivers using their Bionic Biologics platform. The published study showcased the efficacy of heterobifunctional proteomimetic polymers in specifically degrading MYC and another oncogenic driver.